JP2006527727A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006527727A5 JP2006527727A5 JP2006515982A JP2006515982A JP2006527727A5 JP 2006527727 A5 JP2006527727 A5 JP 2006527727A5 JP 2006515982 A JP2006515982 A JP 2006515982A JP 2006515982 A JP2006515982 A JP 2006515982A JP 2006527727 A5 JP2006527727 A5 JP 2006527727A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- increased
- treatment
- day
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000010099 disease Diseases 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 3
- 150000003839 salts Chemical group 0.000 description 3
- -1 4- Toluenesulfonyl Chemical group 0.000 description 2
- 208000000516 Mast-Cell Leukemia Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 206010002425 Angioedemas Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 206010006473 Bronchopulmonary aspergillosis Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 206010019847 Hepatosplenomegaly Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N Imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 208000008585 Mastocytosis Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N Staurosporine Chemical class C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- 206010042440 Sudden infant death syndrome Diseases 0.000 description 1
- 206010046736 Urticarias Diseases 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 201000005311 drug allergy Diseases 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 230000002489 hematologic Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
Description
好ましい部分式Ｒｏ−ＳＯ２ −(式中、Ｒｏは、一般的かつ具体的な意味で上記に定義したヒドロカルビルである)のアシルＡｃ２は、低級アルキルフェニル−スルホニル、典型的に４−トルエンスルホニルである。
遊離形の(とりわけ式Ｉの)化合物と、中間体として、例えば、新規化合物の精製または同定において使用できるそれらの塩を含むそれらの塩の形、ならびにそれらの溶媒和物の密接な関係の観点から、前記および後記で遊離化合物に関する言及は、適当であり、好都合なとき、その対応する塩ならびにその溶媒和物も言及すると理解されるべきである。
前記および後記のラジカルまたは化合物のグループを前記および後記で記載する場合、一般的な定義は、適当であり好都合なとき、前記および後記のより具体的な定義で置き換え得る。
特定のスタウロスポリン誘導体化合物に関して特許出願または科学文献の引用が成されているいずれの場合も、最終産物、医薬製剤および特許請求の範囲の対象をこれらの文献の引用により本発明に包含する。
アレルギー性鼻炎、アレルギー性皮膚炎、薬物アレルギーもしくは食物アレルギー、血管浮腫、蕁麻疹、乳幼児突然死症候群、気管支肺アスペルギルス症、多発性硬化症または肥満細胞症の上記組み合わせでの処置は、いわゆる一次処置、すなわちいかなる化学療法なども以前に受けていない新たに診断された疾患の処置であってよく、またはいわゆる二次処置、すなわち疾患の重症度または段階ならびに患者の全体的状態などに依存して、イマチニブまたはスタウロスポリン誘導体で以前に処置を受けた後の疾患の処置であってもよい。
サイクル３の終わりまでに：疾患進行
−Karnofsky一般状態は減少し始めた；肝脾腫、腹水症、ビリルビンの増加
−ＰＫＣ４１２用量を９１日目から７５mg ｐｏ ｔｉｄに増加させた
−ＰＫＣ４１２を、１０２日目に臓器肥大の悪化を伴う疾患の進行のために停止した、
−ビリルビン(総１４mg／dL)、および末梢血芽細胞の増加(おそらくクローンの、血液学的非−肥満細胞系統疾患と関連する肥満細胞白血病の進行)
−血清ヒスタミンは２５２５ng／dLに再増加し始めた；患者は１１１日目に死亡した。
−Karnofsky一般状態は減少し始めた；肝脾腫、腹水症、ビリルビンの増加
−ＰＫＣ４１２用量を９１日目から７５mg ｐｏ ｔｉｄに増加させた
−ＰＫＣ４１２を、１０２日目に臓器肥大の悪化を伴う疾患の進行のために停止した、
−ビリルビン(総１４mg／dL)、および末梢血芽細胞の増加(おそらくクローンの、血液学的非−肥満細胞系統疾患と関連する肥満細胞白血病の進行)
−血清ヒスタミンは２５２５ng／dLに再増加し始めた；患者は１１１日目に死亡した。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47957503P | 2003-06-18 | 2003-06-18 | |
| US60/479,575 | 2003-06-18 | ||
| PCT/EP2004/006562 WO2004112794A2 (en) | 2003-06-18 | 2004-06-17 | New pharmaceutical uses of staurosporine derivatives |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012101493A Division JP2012144572A (ja) | 2003-06-18 | 2012-04-26 | スタウロスポリン誘導体の新規医薬的使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006527727A JP2006527727A (ja) | 2006-12-07 |
| JP2006527727A5 true JP2006527727A5 (ja) | 2007-07-26 |
| JP5057780B2 JP5057780B2 (ja) | 2012-10-24 |
Family
ID=33539193
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006515982A Expired - Lifetime JP5057780B2 (ja) | 2003-06-18 | 2004-06-17 | スタウロスポリン誘導体の新規医薬的使用 |
| JP2012101493A Pending JP2012144572A (ja) | 2003-06-18 | 2012-04-26 | スタウロスポリン誘導体の新規医薬的使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012101493A Pending JP2012144572A (ja) | 2003-06-18 | 2012-04-26 | スタウロスポリン誘導体の新規医薬的使用 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8575146B2 (ja) |
| EP (1) | EP1638574B1 (ja) |
| JP (2) | JP5057780B2 (ja) |
| CN (2) | CN100457111C (ja) |
| AT (1) | ATE464052T1 (ja) |
| AU (1) | AU2004248909B2 (ja) |
| BE (1) | BE2017C067I2 (ja) |
| BR (1) | BRPI0411563B8 (ja) |
| CA (2) | CA2785950A1 (ja) |
| CY (2) | CY1110179T1 (ja) |
| DE (1) | DE602004026578D1 (ja) |
| DK (1) | DK1638574T3 (ja) |
| ES (1) | ES2344700T3 (ja) |
| FR (1) | FR17C1063I2 (ja) |
| HK (1) | HK1095519A1 (ja) |
| HU (1) | HUS000503I2 (ja) |
| LU (1) | LUC00055I9 (ja) |
| MX (1) | MXPA05013722A (ja) |
| NL (1) | NL300917I2 (ja) |
| PL (1) | PL1638574T3 (ja) |
| PT (1) | PT1638574E (ja) |
| SI (1) | SI1638574T1 (ja) |
| TW (1) | TWI324604B (ja) |
| WO (1) | WO2004112794A2 (ja) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI324604B (en) * | 2003-06-18 | 2010-05-11 | Novartis Ag | New use of staurosporine derivatives |
| US20060014165A1 (en) * | 2003-07-14 | 2006-01-19 | Decode Genetics Ehf. | Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association |
| DE602004020654D1 (de) | 2003-11-18 | 2009-05-28 | Novartis Ag | Hemmer der mutanten form von kit |
| WO2005115385A1 (en) * | 2004-05-24 | 2005-12-08 | Ab Science | Use of c-kit inhibitors for treating acne |
| AU2005274852B2 (en) * | 2004-07-19 | 2011-12-08 | The Johns Hopkins University | FLT3 inhibitors for immune suppression |
| MX2007001155A (es) * | 2004-07-29 | 2007-08-14 | Creabilis Therapeutics Spa | Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1. |
| GB0419159D0 (en) * | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
| CA2606716C (en) * | 2005-05-02 | 2013-07-23 | Novartis Ag | Use of pyrimidylaminobenzamide derivatives for the treatment of systematic mastocytosis |
| AU2006271652B2 (en) * | 2005-07-20 | 2010-04-29 | Peter Valent | Compositions for treatment of systemic mastocytosis |
| RU2443421C2 (ru) * | 2005-11-14 | 2012-02-27 | Университэт Цюрих | Производные стауроспорина для применения при лечении альвеолярной рабдомиосаркомы |
| WO2009092442A1 (en) * | 2008-01-23 | 2009-07-30 | Universidad De Barcelona | Treatment of portal hypertension and related conditions by combined inhibition of the vegf and pdgf signalling pathways |
| WO2012064981A2 (en) | 2010-11-10 | 2012-05-18 | National Jewish Health | Methods to test allergic conditions |
| BR112021008516A2 (pt) | 2018-11-01 | 2021-09-14 | Syros Pharmaceuticals, Inc. | Inibidores de quinase 7 dependente de ciclina (cdk 7) |
| US11325978B2 (en) * | 2018-11-06 | 2022-05-10 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Compositions and methods for treating beta-globinopathies |
| US11839619B2 (en) * | 2019-09-16 | 2023-12-12 | The Regents Of The University Of California | Methods for treatment of pediatric systemic mastocytosis |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4639455A (en) * | 1984-10-02 | 1987-01-27 | Key Pharmaceuticals, Inc. | Means of aiding in the prevention of sudden infant death syndrome |
| JPH0826037B2 (ja) | 1987-01-22 | 1996-03-13 | 協和醗酵工業株式会社 | 生理活性物質ｋ−２５２の誘導体 |
| US5093330A (en) * | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| CA2046801C (en) | 1990-08-07 | 2002-02-26 | Peter D. Davis | Substituted pyrroles |
| EP0518468B1 (en) * | 1991-05-09 | 1999-06-30 | Neurim Pharmaceuticals (1991) Limited | Melatonin containing compositions |
| AR004480A1 (es) * | 1995-04-06 | 1998-12-16 | Amico Derin C D | Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen |
| US6184217B1 (en) * | 1996-06-25 | 2001-02-06 | Cephalon, Inc. | Use of K-252a derivative |
| US6093740A (en) * | 1997-04-30 | 2000-07-25 | Eli Lilly And Company | Therapeutic treatment for skin disorders |
| WO1999062537A1 (en) * | 1998-06-04 | 1999-12-09 | The Rockefeller University | Methods and agents for modulating the immune response and inflammation involving monocyte and dendritic cell membrane proteins |
| GB9903547D0 (en) * | 1999-02-16 | 1999-04-07 | Novartis Ag | Organic compounds |
| MXPA03005139A (es) * | 2000-12-08 | 2004-01-29 | Ortho Mcneil Pharm Inc | Compuestos macroheterociclicos utiles como inhibidores de cinasa. |
| GB0108606D0 (en) * | 2001-04-05 | 2001-05-23 | Novartis Ag | Organic compounds |
| US20030091974A1 (en) * | 2001-06-29 | 2003-05-15 | Alain Moussy | Method for screening compounds capable of depleting mast cells |
| US20050176687A1 (en) * | 2001-06-29 | 2005-08-11 | Alain Moussy | Use of tyrosine kinase inhibitors for treating autoimmune diseases |
| WO2003037347A1 (en) | 2001-10-30 | 2003-05-08 | Novartis Ag | Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity |
| US6998391B2 (en) | 2002-02-07 | 2006-02-14 | Supergen.Inc. | Method for treating diseases associated with abnormal kinase activity |
| JPWO2004091663A1 (ja) | 2003-04-18 | 2006-07-06 | 協和醗酵工業株式会社 | 神経再生薬 |
| WO2004093910A1 (ja) * | 2003-04-22 | 2004-11-04 | Astellas Pharma Inc. | ＰＰＡＲδアゴニストによる脳神経変性疾患治療剤 |
| TWI324604B (en) * | 2003-06-18 | 2010-05-11 | Novartis Ag | New use of staurosporine derivatives |
| DE602004020654D1 (de) | 2003-11-18 | 2009-05-28 | Novartis Ag | Hemmer der mutanten form von kit |
-
2004
- 2004-06-16 TW TW093117368A patent/TWI324604B/zh active
- 2004-06-17 CA CA2785950A patent/CA2785950A1/en not_active Abandoned
- 2004-06-17 MX MXPA05013722A patent/MXPA05013722A/es active IP Right Grant
- 2004-06-17 WO PCT/EP2004/006562 patent/WO2004112794A2/en active Application Filing
- 2004-06-17 AU AU2004248909A patent/AU2004248909B2/en not_active Expired
- 2004-06-17 PL PL04740016T patent/PL1638574T3/pl unknown
- 2004-06-17 CN CNB2004800168219A patent/CN100457111C/zh not_active Expired - Lifetime
- 2004-06-17 US US10/560,669 patent/US8575146B2/en active Active
- 2004-06-17 DK DK04740016.3T patent/DK1638574T3/da active
- 2004-06-17 CN CNA2007101658371A patent/CN101164539A/zh active Pending
- 2004-06-17 JP JP2006515982A patent/JP5057780B2/ja not_active Expired - Lifetime
- 2004-06-17 EP EP04740016A patent/EP1638574B1/en not_active Expired - Lifetime
- 2004-06-17 DE DE602004026578T patent/DE602004026578D1/de not_active Expired - Lifetime
- 2004-06-17 BR BRPI0411563A patent/BRPI0411563B8/pt not_active Application Discontinuation
- 2004-06-17 CA CA2527703A patent/CA2527703C/en not_active Expired - Lifetime
- 2004-06-17 AT AT04740016T patent/ATE464052T1/de active
- 2004-06-17 PT PT04740016T patent/PT1638574E/pt unknown
- 2004-06-17 SI SI200431450T patent/SI1638574T1/sl unknown
- 2004-06-17 ES ES04740016T patent/ES2344700T3/es not_active Expired - Lifetime
-
2007
- 2007-01-18 HK HK07100635.4A patent/HK1095519A1/xx unknown
-
2010
- 2010-07-06 CY CY20101100627T patent/CY1110179T1/el unknown
-
2012
- 2012-04-26 JP JP2012101493A patent/JP2012144572A/ja active Pending
-
2013
- 2013-06-27 US US13/929,438 patent/US20130289018A1/en not_active Abandoned
-
2017
- 2017-12-07 NL NL300917C patent/NL300917I2/nl unknown
- 2017-12-12 LU LU00055C patent/LUC00055I9/fr unknown
- 2017-12-14 HU HUS1700053C patent/HUS000503I2/hu unknown
- 2017-12-19 BE BE2017C067C patent/BE2017C067I2/fr unknown
- 2017-12-22 CY CY2017048C patent/CY2017048I1/el unknown
- 2017-12-28 FR FR17C1063C patent/FR17C1063I2/fr active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006527727A5 (ja) | ||
| ECSP088902A (es) | Derivados de pirazolo[3,4-d]-pirimidina utiles para tratar trastornos respiratorios | |
| US11413278B2 (en) | Compounds and methods for promoting stress resistance | |
| EA200970611A1 (ru) | Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы | |
| CY1109333T1 (el) | 3-[4- ετεροκυκλυλ-1,2,3-τριαζολ-1-υλ]-ν-αρυλο-βενζαμιδια ως αναστολεις της παραγωγης κυτοκινων για τη θεραπευτικη αγωγη χρονιων φλεγμονωδων νοσων | |
| WO2009039397A3 (en) | Substituted amides, methods of making, use thereof for the treatment of diseases such as cancer | |
| NO20092033L (no) | Nye forbindelser | |
| CN106687454B8 (zh) | 作为细胞周期蛋白依赖性激酶(cdk)抑制剂的2h-吲唑衍生物及其医疗用途 | |
| NO20076561L (no) | Imidazoquinoliner som lipid kinaseinhibitorer | |
| ATE442349T1 (de) | Diacylglycerol-acyltransferase-hemmer | |
| EA201000341A1 (ru) | 2-анилинопурин-8-оны в качестве ингибиторов ttk/mps1 для лечения пролиферативных нарушений | |
| NO20082000L (no) | Pyrimidinamidforbindelser som PGDS-inhibitorer | |
| NO20063928L (no) | Substituerte kinolinforbindelser | |
| DE502005010170D1 (de) | Neue langwirksame beta-2-agonisten, und deren verwendung als arzneimittel | |
| ME00354B (me) | Novi lekovi za tretiranje hronićnog opstruktivnog oboljenja pluća | |
| HRP20050103A2 (en) | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion | |
| UA112055C2 (uk) | Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну | |
| MX2012003007A (es) | Sulfonamidas como inhibidores de las proteinas de la familia bcl-2 para el tratamiento de cancer. | |
| EA201270205A1 (ru) | Фармацевтические композиции для лечения рака и других заболеваний и нарушений состояния здоровья | |
| BRPI0519267A2 (pt) | derivado de quinolina, seu uso, produÇço e medicamento contendo o mesmo | |
| JP7393797B2 (ja) | 高サイトカイン血症および重篤なインフルエンザの処置または予防のための方法および化合物 | |
| BR0315462A (pt) | Composto, composição farmacêutica, uso de um composto, método para o tratamento de um sujeito que sofre de uma condição patológica ou de doença susceptìvel de alìvio por antagonismo de receptores de ltd4 e produto de combinação | |
| EA200800071A1 (ru) | Производные бензофуранила как ингибиторы 5-нт6-рецептора | |
| ATE495159T1 (de) | Diaminocyclohexan- und diaminocyclopentanderivate | |
| EA200900269A1 (ru) | Лекарственные комбинации для лечения заболеваний дыхательных путей |